Loss of the endocytic tumor suppressor HD-PTP phenocopies LKB1 and promotes RAS-driven oncogenesis

Oncogenic RAS mutations drive aggressive cancers that are difficult to treat in the clinic, and while direct inhibition of the most common KRAS variant in lung adenocarcinoma (G12C) is undergoing clinical evaluation, a wide spectrum of oncogenic RAS variants together make up a large percentage of un...

Descripción completa

Detalles Bibliográficos
Autores principales: Seong, Chang-Soo, Huang, Chunzi, Boese, Austin C., Hou, Yuning, Koo, Junghui, Mouw, Janna K., Rupji, Manali, Joseph, Greg, Johnston, H. Richard, Claussen, Henry, Switchenko, Jeffrey M., Behera, Madhusmita, Churchman, Michelle, Kolesar, Jill M., Arnold, Susanne M., Kerrigan, Katie, Akerley, Wallace, Colman, Howard, Johns, Margaret A., Arciero, Cletus, Zhou, Wei, Marcus, Adam I., Ramalingam, Suresh S., Fu, Haian, Gilbert-Ross, Melissa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cold Spring Harbor Laboratory 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9900931/
https://www.ncbi.nlm.nih.gov/pubmed/36747658
http://dx.doi.org/10.1101/2023.01.26.525772

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9900931/
https://www.ncbi.nlm.nih.gov/pubmed/36747658
http://dx.doi.org/10.1101/2023.01.26.525772

Ejemplares similares